Tianjin Pharmaceutical Da Ren Tang (SGX:T14, SHA:600329) has proposed to dispose its remaining 12% stake in Tianjin TSKF Pharmaceutical to Haleon China and Haleon CH, according to a Tuesday filing with the Singapore Exchange.
The company has proposed to transfer 4.6% equity in TSKF to Haleon China for 622.3 million yuan and 7.4% interest to Haleon CH for around 1.0 billion yuan.
Proceeds from the disposal will be used for business expansion, enhancing research and development capabilities and for working capital and general corporate purposes, Tianjin Pharma said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。